All News

At 4 years post-surgery, men receiving Rezum had preserved and/or improved sexual function and better lower urinary tract symptoms secondary to benign prostatic hyperplasia.

The FDA has approved enzalutamide for use with or without a GnRH analog therapy for the treatment of patients with nonmetastatic castration-sensitive prostate cancer.

Although traditional payment and communication methods remain relevant, the survey highlights a paradigm shift in patients' billing expectations overall.

Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.

"This is the 15th year [of LUGPA,] and I think I've gone maybe 12, 13 years in a row or so, almost every year," says Lawrence Gervasi, MD.

The novel TKI zanzalintinib demonstrated early efficacy signals with manageable toxicity in patients with advanced clear-cell renal cell carcinoma.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.

"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.

Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.

Circulating tumor DNA is showing promise as a tool to guide decisions on treatment intensification and de-escalation in patients with renal cell carcinoma.

Translocation renal cell carcinoma is a rare type of RCC that is typically characterized by gene fusions involving the MiT family of transcription factors including TFE3, TFEB, TFEC, and MiTF.

Notably, the study represents a 57% increase in the number of non-European participants compared with previous prostate cancer genome-wide association studies.

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.

The CPT code will be effective beginning July 1, 2024.

Researchers utilized the PI-QUAL scoring system to assess 355 mpMRI exams performed at 41 facilities in 18 countries.

"The end of the year presents a good opportunity to regroup, close out 2023 in the strongest position possible, and ready yourself for 2024," writes Jeff Witz, CFP.

"This is our biggest meeting ever in our 15-year history [with] almost 1100 people here," says Evan R. Goldfischer, MD, MBA, FACS.

At the time of the data cutoff, a maximum tolerated dose of 225Ac-J591 had not yet been reached.

“Preclinical and clinical findings thus far indicate that SAR-Bombesin holds significant potential for improving the diagnosis and treatment of prostate cancer,” said lead principal investigator Andrei Iagaru, MD.

"All of our tools, including genomics and MRI, enable us to do a better job of risk stratifying [patients] to have a more appropriate shared decision-making discussion [about active surveillance]," explains David Morris, MD.

Data showed that plasma oxalate levels were maintained through 24 months of treatment with lumasiran.

"Patients shouldn’t be making the decision to do active surveillance without understanding what that means and what their other options are,” one panelist said.

“Radiation therapy continues to expand its role, especially if you start talking about [patients with] the ultra high–risk [prostate cancer] or node-positive [disease] and beyond,” says Daniel Spratt, MD.

“We went to medical school to take care of patients, not to service the computer, which is what we do for a large part of our daily work," said Inderbir Gill, MD.

“There’s a lot of clinical trial activity in the [bladder cancer realm], and hopefully [new therapies will] keep adding to our armamentarium of [treatment strategies] we can offer patients,” said Gautam Jayram, MD.

In this interview, Scott A. MacDiarmid, MD, discusses health care professional burnout, including how he came to be interested in the topic and what can be done to prevent burnout.

"An educated patient is one that's always going to want to be more involved in trying to make themselves better; they're going to be an empowered patient,” says Thomas J. Mueller, MD.